Shire acquires Lumena Pharmaceuticals for $260 million plus milestone payments

Shire plc and Lumena Pharmaceuticals, Inc., a biopharmaceutical company with rare disease pipeline assets, announce the acquisition of Lumena Pharmaceuticals by Shire.The acquisition of Lumena strengthens Shire’s already valuable and robust pipeline. It complements Shire’s strategic focus on Rare Diseases and provides a future growth path for Shire’s Gastrointestinal business, which generated revenues of over $800 million in 2013.Lumena Pharmaceuticals brings to Shire two new oral therapeutic compounds; LUM001, in Phase II with four potential orphan indications and LUM002, ready to enter Phase II later in 2014.The acquisition of Lumena brings Shire into the field of rare cholestatic liver diseases.